BIO-Europe partnering is the one-to-one meeting system at the centre of the annual BIO-Europe conference, held this year in Cologne from 9 to 11 November 2026. For APAC biotech and life science companies using the event as a route into the European market, the outcome of those meetings is largely settled before anyone boards a flight: which partners you request, how your partneringONE profile reads, and whether your materials answer the questions a European business development team asks in the first ten minutes. This guide sets out how to prepare for each of those stages, from targeting through to follow-up.
Key takeaway: BIO-Europe partnering rewards preparation more than presence. The APAC companies that leave with real follow-up conversations are usually the ones whose target list, profile and non-confidential materials were built for a European business development reader before the event opened.
What is BIO-Europe partnering, and why does it matter for APAC companies?
BIO-Europe partnering is a scheduled meeting system in which registered delegates request short one-to-one meetings with each other through a platform called partneringONE. According to the organisers’ partnering guidance, access is granted once registration is paid and approved, and accepted meetings are scheduled automatically, so neither side has to negotiate a time slot. The event draws delegates from more than 60 countries, which makes it one of the few places where an APAC biotechnology company can meet European pharma, mid-sized specialty companies, investors and service providers in a single week.
For companies based in Singapore, Korea, Japan, Taiwan or Australia, that concentration matters. Building European relationships from Asia usually means slow email threads across time zones and a long wait for a first call, and partnering compresses that into three days. It also exposes gaps quickly. Panellists at the Asia Bio Partnering Forum in Singapore recently argued that APAC biotechs with global ambitions need to settle corporate structure, intellectual property, financing and clinical development decisions from the outset. Those are exactly the topics a European partner will probe in a first meeting.
Partnering outcomes are mostly decided before the first meeting request
Strong life science partnering starts with a short, deliberate target list. Before partneringONE opens, define what a good outcome looks like for this event: a licensing discussion for a specific asset, a co-development partner for European trials, a CDMO for scale-up, or introductions to investors who back companies expanding into Europe. Then filter registrants against that objective instead of requesting meetings with every recognisable name. Large pharma business development teams receive heavy request volumes, while European mid-sized companies and regional specialists are often more responsive and more realistic partners for an early asset.
The organisers note that completed profiles are more likely to have meeting requests accepted, and that specific subject lines are less likely to be overlooked than generic ones. A company profile should state the modality or platform, the lead indication or application, the development stage and the type of partnership sought, in plain commercial language. A meeting request should explain in two or three sentences why this particular partner is relevant: an overlap with their therapeutic focus, a gap in their pipeline, or a capability they are known to be building. A request that reads as a mass mailing is easy to decline.
What do European BD teams look for in a first partnering meeting?
European business development teams use a first partnering meeting to decide whether an opportunity deserves a confidential follow-up, so they listen for fit, evidence and risk before they listen for the full scientific story. The difference between a science-first presentation and a partner-ready one is mostly a difference of order and emphasis.
| Partnering meeting element | Science-first version | Partner-ready version |
|---|---|---|
| Opening | Platform mechanism and publication history | The problem addressed, the asset, and why it fits this partner |
| Data | Every experiment, in chronological order | The two or three datasets that reduce risk for the next step |
| Intellectual property | A list of patent filings | Ownership, European territory coverage and freedom to operate status |
| Regulatory path | Home-market regulatory interactions | How the programme maps to EMA expectations and European trial sites |
| The ask | Open to partnership discussions | A specific deal type, scope and next step |
The partner-ready version keeps the scientific substance intact. What changes is the sequence: it starts from the partner’s commercial question and brings in the data that answers it. This is the same discipline behind positioning and messaging for biotech companies, and it is often the hardest part to do from inside the company, because the team knows the science too well to see which parts a newcomer needs first.
A partnering deck answers different questions from an investor deck
A partnering deck has to answer a corporate partner’s questions, which overlap only partly with an investor’s. An investor asks whether the company can reach its next value inflection point with the capital raised. A pharma or biotechnology partner asks whether the asset fits its portfolio strategy, what development would cost in their hands, and whether the data package will survive internal review. Many APAC teams arrive with a lightly edited fundraising deck, which tends to underserve those questions. Experienced pitch deck support treats the partnering version as its own document, with confidential data held back until a CDA is signed.
The deck rarely travels alone. A one-page asset summary, a partneringONE profile that matches it, and a company website that a BD lead can check in two minutes all form part of the first impression. Keeping these marketing materials consistent in language and claims matters more than polish, because inconsistency between documents is one of the quickest ways to lose credibility with a technical reviewer.
Strategy note: Treat the non-confidential deck as the document a BD lead forwards internally after the meeting. If it cannot make the case without you in the room, it is unlikely to reach the next review.
How should APAC teams plan the weeks around BIO-Europe?
APAC teams get the most from BIO-Europe when they treat it as a two-month project with the event in the middle, because targeting, materials and follow-up each need their own time.
Partnering preparation timeline: five stages from objective to follow-up.
- Six to eight weeks out: agree the partnering objective, shortlist target companies and assign an owner to each conversation
- When partneringONE opens: publish company and personal profiles, then send tailored meeting requests before calendars fill
- Two weeks out: finalise the non-confidential deck and one-page summary, and rehearse a ten-minute version of the story
- During the event: record each partner’s stated priorities and the agreed next step straight after every meeting
- Within a week after: send tailored follow-ups, share the agreed materials and move promising conversations towards a CDA
Two practical points apply to teams flying in from Asia. Follow-up needs to happen while the conversation is fresh, which means drafting messages during the event rather than after the return flight. And because European partners will need calls during their own working hours, it helps to agree a follow-up slot that works across both time zones before the meeting ends.
European partnering success starts with how your science is framed
For APAC life science companies, BIO-Europe partnering is one of the most efficient routes into European relationships, and the BIO-Europe Spring edition offers a second opportunity each year. The same approach applies to CROs, CDMOs, diagnostics and life science tools companies attending to find clients or distribution partners. The companies that convert meetings into partnerships tend to share the same habits: a narrow target list, profiles and requests written for the reader, materials that answer partner questions in the order they are asked, and disciplined follow-up. This is achievable for a small team, provided it decides before the event what a European partner needs to understand about the science and why it matters to them.
Preparing for partnering meetings in Europe? Biond helps APAC biotech and life science companies shape their positioning, partnering materials and profile copy for European business development audiences, and we are happy to talk through your plans.
Frequently Asked Questions
Biond Marketing describes BIO-Europe partnering as a scheduled one-to-one meeting system run through the partneringONE platform, where registered delegates request, accept or decline meetings with each other. Accepted meetings are placed in both calendars automatically. Access opens once registration is paid and approved, and calendars fill quickly, so early requests with specific subject lines have the best chance of acceptance.
Biond Marketing recommends that APAC biotech companies start preparing for BIO-Europe partnering six to eight weeks before the event. That leaves time to agree a partnering objective, build a target list, and have profiles and materials ready when partneringONE opens. Teams that start after the system opens often find that the partners they most want to meet have already filled their schedules.
Biond Marketing sees BIO-Europe as relevant well beyond therapeutics developers, including CROs, CDMOs, diagnostics companies, scientific instrument makers and research service providers. These companies use partnering to meet biotechnology clients, find European distribution or co-development partners, and build relationships with pharma outsourcing teams. The same rules apply: a focused target list, a profile that states the service or product plainly, and materials written for the buyer’s commercial questions.
Biond Marketing advises that a non-confidential partnering deck should cover the problem the asset or platform addresses, the key data that reduces risk for the next step, intellectual property ownership and European coverage, the development or regulatory path, and a specific partnership ask. It should make sense without a presenter, because BD teams often forward it internally. Confidential data belongs in the follow-up, after a CDA is signed.
